Sustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation
Source abstract
Abstract
This study developed a hypoxia-responsive N-803 nanogel (BiA-N-803 NG) for controlled release of an IL-15 superagonist to enhance CAR-T cell therapy in multiple myeloma. The nanogel was dual-targeted to CD138 and TIM-3 and exhibited stable, hypoxia-triggered release properties. In vitro analyses demonstrated that BiA-N-803 NG promoted CAR-T cell expansion, memory programming, and antitumor function, characterized by increased memory T-cell subsets and reduced exhaustion phenotypes. Transcriptomic profiling identified activation of the FOXO1 signaling axis as a key mechanism underlying CAR-T cell memory differentiation. In vivo studies further showed improved CAR-T cell persistence, enhanced NK cell recruitment, and reduced infiltration of immunosuppressive cells, collectively leading to a remodeled immune microenvironment and improved therapeutic durability in multiple myeloma.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CAR-T cell therapy research · Multiple Myeloma Research and Treatments · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Molecular basis of multiple myeloma10.48095/ccko202427 ↗
2. Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients10.1186/s12920-025-02116-5 ↗
3. A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab10.37349/etat.2025.1002300 ↗
4. Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting10.1186/s40164-025-00643-6 ↗
5. CAR T-cell therapy in multiple myeloma: more room for improvement10.1038/s41408-021-00469-5 ↗
6. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies
7. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma10.1186/s13045-020-01001-1 ↗
8. The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR10.1016/j.intimp.2023.111239 ↗
9. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity10.1016/j.canlet.2022.215710 ↗
10. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability10.1172/JCI133215 ↗
11. 4-1BB-Based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody10.3390/ijms24044197 ↗
12. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma10.3390/cancers13092018 ↗
13. Myeloid-derived suppressor cells: the green light for myeloma immune escape10.1016/j.blre.2016.04.002 ↗
14. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma10.1186/s12943-022-01655-0 ↗
15. Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence10.7759/cureus.65291 ↗
16. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy10.1158/2159-8290.CD-20-1677 ↗
17. Improving CAR T-Cell persistence
18. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion10.1136/jitc-2023-008429 ↗
19. Tumor microenvironment pH-responsive pentagonal gold prism-based nanoplatform for multimodal imaging and combined therapy of castration-resistant prostate cancer10.1016/j.actbio.2022.01.012 ↗
20. Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment10.1016/j.mattod.2023.03.006 ↗
21. Liposome-integrated hydrogel hybrids: promising platforms for cancer therapy and tissue regeneration10.1016/j.jconrel.2024.03.008 ↗
22. FoxO1 controls effector-to-memory transition and maintenance of functional CD8 T cell memory10.4049/jimmunol.1300331 ↗
23. FOXO1 is a master regulator of memory programming in CAR T cells10.1038/s41586-024-07300-8 ↗
24. Prosurvival IL-7–Stimulated weak strength of mTORC1-S6K controls T cell memory via transcriptional FOXO1–TCF1–Id3 and metabolic AMPKα1–ULK1–ATG7 pathways10.4049/jimmunol.2100452 ↗
25. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells10.1007/s00262-020-02749-8 ↗
26. N-803: a double-edged sword in haplo-NK therapy10.1182/blood.2021014789 ↗
27. IL-15 transpresentation by ovarian cancer cells improves CD34 + progenitor-derived NK cell's anti-tumor functionality10.1080/2162402X.2025.2465010 ↗
28. Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers10.4049/jimmunol.2100066 ↗
29. CD44-mediated tumor homing of hyaluronic acid nanogels for hypoxia-activated photodynamic therapy against tumor10.1016/j.colsurfb.2023.113395 ↗
30. Hypoxia-degradable and long-circulating zwitterionic phosphorylcholine-based nanogel for enhanced tumor drug delivery10.1016/j.apsb.2020.08.012 ↗
31. Engineered macrophage membrane‐coated S100A9‐siRNA for ameliorating myocardial ischemia‐reperfusion injury10.1002/advs.202403542 ↗
32. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma10.1038/s41392-023-01702-2 ↗
33. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion10.1016/j.ebiom.2022.103941 ↗
34. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site10.1186/s13045-016-0345-3 ↗
35. Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma10.1016/j.blre.2025.101256 ↗
36. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells10.1186/s13045-022-01255-x ↗
37. Epigenetic reprogramming holds promise in enhancing anti-tumor efficacy of CAR T cell therapy10.1016/j.biotechadv.2025.108649 ↗
38. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy10.1182/blood.2021011532 ↗
39. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy10.1038/s41586-024-07242-1 ↗
40. Nanomaterials for cancer therapy: current progress and perspectives10.1186/s13045-021-01096-0 ↗